Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction
Clinical trial NCT03802396 · COMPLETED
Trial details
- NCT number
- NCT03802396
- Sponsor
- Miles Berger, MD PhD
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-15
- Primary completion
- 2022-12-28
- Enrollment
- 203
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.